Fusion Expert Ian Chapman Appointed to Lead UK Research and Innovation
Summary:
Ian Chapman, who revitalized Britain’s fusion program post-Brexit, will become chief executive of UKRI in June. The physicist faces immediate challenges with flat budgets amid economic struggles as he takes over the £9 billion research funding agency.
PD-1/VEGF Bispecific Antibodies Emerge as Potential Keytruda Successor
Summary:
New dual-targeting cancer drugs show promise after ivonescimab dramatically outperformed Keytruda in lung cancer trials.
Sofinnova Raises €1.2B to Fuel Next Generation of Life Sciences Companies
Summary:
European VC firm Sofinnova Partners secured €1.2B for biotech investments, planning to support 50-60 new healthcare companies.
Silence Therapeutics Postpones Phase III Trial for Cardiovascular Drug Until Finding Partner
Summary:
Unable to fund late-stage trials alone, Silence delays zerlasiran development despite strong 90% Lp(a) reduction data.
BridgeBio Oncology Goes Public Through $450M SPAC Deal in Surprise Return to 2021-Era Trend
Summary:
Cancer-focused BridgeBio spinout merges with Helix SPAC to secure funding for three clinical programs targeting KRAS mutations.
